NCT07107919Recruiting
Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective
Source: ClinicalTrials.gov · Last updated 6 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR \< 30 mL/min/1.73 m²). Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 31 Jul 2025
- Start date
- 30 Jul 2025
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07107919
What you commit to
- Study type: Observational
- Planned participants: 60
- From 30 Jul 2025 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindications to PET/MR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties.
- History of allergy or hypersensitivity to gadolinium-based contrast agents.
- Presence of malignant tumors or other serious progressive diseases.
- Patients with severe cardiac conditions, such as advanced heart failure, severe valvular disease, or cardiomyopathies.
- Presence of severe systemic or localized infections, or other serious comorbid conditions.
Other
- Women who are planning to conceive, currently pregnant, or breastfeeding.
- Hemodynamic instability.
- Incomplete clinical data.
- Any other reason deemed by the investigators to make the subject unsuitable for participation, including inability or unwillingness to comply with study procedures and requirements.
- Determined by the investigators to be inappropriate for inclusion in the study.
Who the study is looking for
- Age between 18 and 80 years, regardless of sex.
- Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines.
- Complete clinical data available.
- Written informed consent for participation and for undergoing 18F-FAPI PET/MR imaging is obtained from the patient or their legal guardian.
- Female participants must agree to use effective contraception during the study and for at least 6 months after its completion (e.g., sterilization, intrauterine hormonal devices, condoms, hormonal contraceptives, abstinence, or vasectomized partner). Male participants must also agree to use contraception during the study and for 6 months after its completion.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Affiliated Hospital of Qingdao University Coordinator of this site? Confirm its status | Qingdao | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.